select trial semaglutide cardiovascular outcomes without diabetes 2023 VisualAbstract: and in Obesity Semaglutide and cardiovascular outcomes in

In acid sphingomyelinase knock-out mice, which mimic a neurovisceral acid sphingomyelinase deficiency (ASMD) characterized by cellular accumulation of sphingomyelin, the effects of a choline-free diet decreased the activation of liver macrophages and microglia, but it did not significantly alter sphingomyelin levels due to compensatory mechanisms involving methionine metabolism (101)

For those who want the look of a tan without the risks, UV-free self-tanning options are available and safe

Treatment begins with a 2.5 mg weekly dose for 4 weeks, intended for initiation only, before up-titration in 2.5 mg increments to a maintenance dose of 5-15 mg weekly, depending on individual response and tolerability

Ozempic, a brand name for the drug semaglutide, has become increasingly popular for weight loss purposes, however it is actually intended to treat type 2 diabetes

If you like this article, please like/share, and thank you

doi: 10.1152/ajpendo.00429.2014 105 BanKKimKHChoCKSauvMDiamandisEPBackxPHet al